Berth-Jones J, Exton LS, Ladoyanni E, Mohd Mustapa MF, Tebbs V,
Yesudian PD, Levell NJ
British Association of Dermatologists guidelines for the safe
and effective prescribing of oral ciclosporin in dermatology 2018
Br J Dermatol. 2019 Jan 17. doi: 10.1111/bjd.17587. [Epub
ahead of print] PubMed PMID: 30653672.
Mrowietz U, Szepietowski JC, Loewe R, van de Kerkhof P, Lamarca R,
Ocker WG, Tebbs VM, Pau-Charles I.
Efficacy and safety of LAS41008 (dimethyl fumarate) in adults
with moderate-to-severe chronic plaque psoriasis: a randomized,
double-blind, Fumaderm(®) - and placebo-controlled trial (BRIDGE)
Br J Dermatol 2017 Mar;176(3):615-623
Van de Kerkhof P, Szepietowski JC, Loewe R, Lamarca R, Ocker WG,
Tebbs VM, Pau-Charles I, Mrowietz U.
Efficacy and safety of LAS41008 (dimethyl fumarate) in adults
with moderate-to-severe chronic plaque psoriasis: Results of the
BRIDGE trial Abstract presented at 25th EADV, Vienna Austria,
28 Sep to 2 Oct, 2016
Van de Kerkhof P, Szepietowski JC, Loewe R, Lamarca R, Ocker WG,
Tebbs VM, Pau-Charles I, Mrowietz U.
Treatment with LAS41008 (dimethyl fumarate) improves
health-related quality of life and has a positive impact on the
patient’s benefit index in adults with moderate-to-severe chronic
plaque psoriasis: Results of the BRIDGE trial Abstract
presented at EADV, Vienna Austria, 28 Sep to 2 Oct, 2016
Mrowietz U, Ocker WG, Tebbs V, Rodriguez R, and Lamarca R
LAS41008 (Dimethyl fumarate) improves health-related quality
of life and physician's global assessment scores in the treatment of
moderate-to-severe chronic plaque psoriasis: the BRIDGE study
E-Poster presented at 74th Annual Meeting of the American
Academy of Dermatology, Washington, D.C., March 4-8, 2016
Paul C, Stalder J F, Goujon Henry C, Bedane C, Lahfa M, Bernard P,
Brault Y, Thaci D, Vincendon P, Kielar D, Tebbs V
Evaluation de la satisfaction des patients concernant les
dispositifs d’injection d’etanercept au cours du traitement du
psoriasis par biothérapie: une étude randomisée comparant un stylo
auto-injecteur et une seringue préremplie Abstract C131
presented at the Journeés Dermatologiques de Paris, 7-11 Dec 2010,
Paris
Paul C, Stadler JF, Thaci B, Vincendon P, Kielar D & Tebbs V
Comparison of patient satisfaction for 2 different etanercept
delivery systems in psoriasis Abstract presented at 7th EADV
Spring Symposium, 13-16 May 2010, Cavtat, Croatia
Dummer R, Hauschild A, Becker JC, Grob JJ, Schadendorf D, Tebbs V,
Skalsky J, Kaehler KC, Moosbauer S, Clark R, Meng TC, Urosevic M.
An Exploratory Study of Systemic Administration of the
Toll-like Receptor-7 Agonist 852A in Patients with Refractory
Metastatic Melanoma. Clin Cancer Res. 2008 Feb 1;14(3):856-64
Gollnick H, Guillén Barona C, Frank RGJ, Ruzicka T, Megahed
M, Haynes I, Tebbs V, Stampone P
Recurrence rates of superficial basal cell carcinomas 3 years
after treatment with imiquimod 5x/week for 6 weeks Abstract
presented at 15th Congress of the European Academy of Dermatology
and Venereology, 4 – 8 Oct, 2006, Rhodes, Greece
Gollnick H, Guillén Barona C, Frank RGJ, Ruzicka T, Megahed
M, Haynes I, Tebbs V, Stampone P
3-Year Recurrence Rates of Superficial Basal Cell Carcinomas
after Treatment with Imiquimod 5x/week for 6 weeks Abstract
P1902 presented at American Academy of Dermatology Summer Meeting,
San Diego, CA, US, July 26-30 2006
Gollnick H, Barona CG, Frank RG, Ruzicka T, Megahed M, Tebbs V,
Owens M, Stampone P
Recurrence rate of superficial basal cell carcinoma following
successful treatment with imiquimod 5% cream: interim 2-year results
from an ongoing 5-year follow-up study in Europe. Eur J
Dermatol. 2005 Sep-Oct;15(5):374-81
Tebbs V, Eedy D
William Wallace and his introduction of Hydriodate of Potash
in the 19th century as an effective treatment for syphilis
Abstract presented at BAD 85th Annual Meeting, 4- 7 July 2005,
Glasgow Br J Dermatol 2005;153, Suppl 1: 53 [Abstract H-5]
Schulze HJ, Cribier B, Requena L, Reifenberger J, Ferrándiz
C, Garcia Diez A, Tebbs V, McRae S
Imiquimod 5% cream for the treatment of superficial basal cell
carcinoma: results from a randomized vehicle-controlled phase III
study in Europe Br J Dermatol 2005;152:939–947
Gollnick H, Guillen Barona C, Frank R, Ruzicka T, Megahed M, Haynes
I, Tebbs V, Hawkinson R
Efficacy by clinical evaluation of imiquimod 5% cream in the
treatment of superficial basal cell carcinoma: initial results from
an ongoing, long-term follow-up study in Europe Abstract P480
presented at American Academy of Dermatology 62nd Annual Meeting,
Washington, DC, US, Feb 6-11 2004
Gollnick H, Guillén Barona C, Frank RGJ, Ruzicka T, Megahed
M, Haynes I, Tebbs V, Hawkinson R
Clinical efficacy of imiquimod 5% cream in the treatment of
superficial basal cell carcinoma: initial results from an ongoing,
long-term five years follow-up study in Europe Abstract
presented at 12th Congress of the European Academy of Dermatology
and Venereology, 15 – 18 October, 2003, Barcelona, Spain.
Gollnick H, Guillén Barona C, Frank RGJ, Ruzicka T, Megahed
M, Haynes I, Tebbs V, Hawkinson R
Clinical efficacy of imiquimod 5% cream in the treatment of
superficial basal cell carcinoma: initial results from an ongoing,
long-term five years follow-up study in Europe Abstract
presented at 9th World Congress on Cancers of the Skin 7-10 May,
2003, Seville, Spain
Jenkins D, Tebbs VM, Seth R
Prospective study of p16 in immunohistochemistry in routine
diagnosis of cervical intraepithelial neoplasia Abstract
presented at the Joint Meeting of the British Division of the
International Academy of Pathology and the Pathological Society of
Great Britain and Ireland, Liverpool, 3rd – 6th July 2001
Aspinall P, Clark R, Kell P, Holder M, Miles K, Kinghorn G, Herman
S, Bradbury C, Tebbs V
Quality of life of women with diagnosed bacterial vaginosis
(BV) International Journal of Gynecology and Obstetrics
1999;67:S44
Flavell Matts SG, Hazelman BL, Houben H, Dhondt E, Tebbs VM
Controlled study of once-daily, sustained-release ibuprofen in
osteoarthritis Curr Therap Res 1993; 53: 394 – 400
Sanz Frutos P, Moreno E, Tebbs VM
Therapeutic activity and tolerability of sustained-release
flurbiprofen (Froben SR) and piroxicam in osteoarthritis of the knee
Br J Rheumatol 1992; 31 (Suppl 2): 160
Haanen HCM, Jacobs PJC, Schardijn GHC, Nayer J De, Hauwaert C,
Vanderstraeten G, Vlottes PW, Tebbs VM
Efficacy and tolerability of sustained-release flurbiprofen
(Froben Retard, Froben Suscap) in arthritis: hospital based studies
in Belgium and Holland Br J Rheumatol 1992; 31 (Suppl 2): 159
Muldoon CG, Tebbs VM, Goulder MA
An open comparison of a once daily dosage of sustained-release
ibuprofen (Brufen Retard) versus standard ibuprofen to assess short
and long term tolerability in the elderly Hung Rheum 1991; 32
(Suppl 1): 362
Muldoon CG, Tebbs VM, Munroe AJ
A double-blind clinical trial comparing 24 hour control of
arthralgia with sustained-release ibuprofen (Brufen Retard) and
piroxicam in elderly patients with osteoarthritis of the hip or knee
Hung Rheum 1991; 32 (Suppl 1): 361
Azanza JR, Macias HJJ, Tebbs VM
Randomized double-blind clinical trial for investigating the
efficacy and tolerance of Flurbiprofen Retard in comparison with
tiaprofenic acid in the treatment of active rheumatoid arthritis
Hung Rheum 1991; 32 (Suppl 1): 361
Tebbs VM, Muldoon CG, Goulder MA
An open parallel group, multicentre study to assess the
comparative efficacy and tolerability of sustained-release ibuprofen
(Brufen Retard) and standard ibuprofen Hung Rheum 1991; 32
(Suppl 1): 360
Baumgartner H, Scrimshire JA, Tebbs VM
A single blind, parallel group, multiple dose study of the
efficacy and tolerability of sustained release ibuprofen and
sustained release diclofenac sodium in the treatment of
osteoarthritis Scand J Rheumatol 1990; Suppl 85: 61
Franchimont P, Houben H, Tebbs VM
A double blind study to compare a once daily dose of 1600mg
sustained release ibuprofen with standard 400mg ibuprofen tablets
given four times daily in patients with osteoarthritis of the knee
Scand J Rheumatol 1990; Suppl 85: 61
Tebbs VM, Martin AJ
Affective disorders in the elderly: 1000 patient GP trial on
new drug Geriatric Medicine 1987; Oct: 17 - 21